Trials / Completed
CompletedNCT01908140
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in Symptomatic Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 933 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the efficacy, safety and tolerability of aclidinium bromide/formoterol fumarate and salmeterol/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aclidinium Bromide / Formoterol Fumarate | |
| DRUG | Salmeterol / Fluticasone |
Timeline
- Start date
- 2013-09-01
- Primary completion
- 2014-08-01
- Completion
- 2014-08-01
- First posted
- 2013-07-25
- Last updated
- 2016-03-07
- Results posted
- 2016-03-07
Locations
126 sites across 14 countries: Austria, Bulgaria, Canada, Czechia, France, Germany, Hungary, Italy, Lithuania, Netherlands, Poland, South Africa, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01908140. Inclusion in this directory is not an endorsement.